Gliomatosis Cerebri Latest Advances

Find the Latest Research About Gliomatosis Cerebri

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 192104 publications

Comments on chemoradiotherapy in IDH wild-type/TERT-mutant grade 2/3 gliomas.

Comments on chemoradiotherapy in IDH wild-type/TERT-mutant grade 2/3 gliomas.

Journal: Cancer

Published: April 15, 2026

Reply to "Comments on chemoradiotherapy in IDH wild-type/TERT-mutant grade 2/3 gliomas".

Reply to "Comments on chemoradiotherapy in IDH wild-type/TERT-mutant grade 2/3 gliomas".

Journal: Cancer

Published: April 15, 2026

Synergistic action of JNK activation and BChE inhibition: a novel anti- glioblastoma compound with neuroprotective profile.

Synergistic action of JNK activation and BChE inhibition: a novel anti- glioblastoma compound with neuroprotective profile.

Journal: Future medicinal chemistry

Published: April 15, 2026

FOXR2-activated CNS neuroblastoma: Characterized by variable structural disruption of the FOXR2 regulatory region, recurrent copy number alterations, and elevated FOXR2 expression.

FOXR2-activated CNS neuroblastoma: Characterized by variable structural disruption of the FOXR2 regulatory region, recurrent copy number alterations, and elevated FOXR2 expression.

Journal: Neuro-oncology pediatrics

Published: April 14, 2026

EXPRESSION OF CONCERN: Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.

EXPRESSION OF CONCERN: Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.

Journal: British journal of pharmacology

Published: April 14, 2026

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 14, 2026

Ophthalmological manifestations of neuroblastoma - A retrospective multicenter study.

Ophthalmological manifestations of neuroblastoma - A retrospective multicenter study.

Journal: Pediatric hematology and oncology

Published: April 14, 2026

PARP7 inhibition and a STING agonist potentiate radiation-induced immunogenicity in glioblastoma.

PARP7 inhibition and a STING agonist potentiate radiation-induced immunogenicity in glioblastoma.

Journal: Oncoimmunology

Published: April 14, 2026

Injectable Trojan Horse Hydrogel Unleashing Penetrable and Immunostimulatory Nanomicelles for Postoperative Treatment of Glioblastoma.

Injectable Trojan Horse Hydrogel Unleashing Penetrable and Immunostimulatory Nanomicelles for Postoperative Treatment of Glioblastoma.

Journal: ACS nano

Published: April 13, 2026

Biotin-Decorated Inulin-Based Polymeric Micelles Unveil Their Dual-Targeting Ability for the Potential Treatment of Glioblastoma Multiforme through the In Vitro and In Vivo Investigations.

Biotin-Decorated Inulin-Based Polymeric Micelles Unveil Their Dual-Targeting Ability for the Potential Treatment of Glioblastoma Multiforme through the In Vitro and In Vivo Investigations.

Journal: Molecular pharmaceutics

Published: April 13, 2026

Glioprotective effects of gM-CSF against glutamate-induced oxidative stress, genotoxicity, and inflammation in rat C6 cells.

Glioprotective effects of gM-CSF against glutamate-induced oxidative stress, genotoxicity, and inflammation in rat C6 cells.

Journal: Toxicology mechanisms and methods

Published: April 13, 2026

Discovery of a Highly Potent and Selective mTOR Inhibitor that Strongly Suppresses Glioblastoma Multiforme Cell Growth.

Discovery of a Highly Potent and Selective mTOR Inhibitor that Strongly Suppresses Glioblastoma Multiforme Cell Growth.

Journal: Journal of medicinal chemistry

Published: April 13, 2026

Showing 1-12 of 192,104

Last Updated: 04/28/2026